Biovitrum Aims to Spin Out Cambridge Biotechnology

Biovitrum AB announced the initiation of a process aiming to spin out its small molecule UK based R&D subsidiary Cambridge Biotechnology (CBT) and a range of primary care projects.
MSNBC